TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33303557

Group type: EXPERIMENTAL
Intervention: Hospitalisation for COPD after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exacerbation frequency after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worsening of body mass index after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airflow obstruction after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyspnoea and exercise (BODE index) after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health status (St George's Respiratory Questionnaire (SGRQ)) after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persistence of systemic inflammation after 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 s (FEV1) at 3 years
Number of subjects: 0
Study: 33303567

Group type: EXPERIMENTAL
Intervention: On-site treatment with sofosbuvir/velpatasvir
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Link-to-care treatment
Number of subjects: 2323

Group type: COMPARATOR
Intervention: Overall HCV-viremic rate
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: HCV microelimination
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: 'No-C HD' (no HCV-viremic subjects)
Number of subjects: 2323
Study: 33303707

Group type: EXPERIMENTAL
Intervention: Rixubis (recombinant factor IX, nonacog gamma)
Number of subjects: 58
Study: 33303745

Group type: EXPERIMENTAL
Intervention: Inhibition of RANK signaling in mouse tumor cells
Number of subjects: 0
Study: 33303900

Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) DM (+)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) DM (-)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Sleep apnea (-) DM (+)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Sleep apnea (-) DM (-)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) and DM (+)
Number of subjects: 1007
Study: 33304267

Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive VRRS followed by telerehabilitation (36 sessions of home-based cognitive VRRS training, three sessions per week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive VRRS followed by at-home unstructured cognitive stimulation (36 sessions, three sessions per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Face-to-face cognitive treatment as usual (12 sessions)
Number of subjects: 49
Study: 33304282

Group type: EXPERIMENTAL
Intervention: 800 mg CBD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg THC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both cannabinoids (800 mg CBD and 20 mg THC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33304914

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO2R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lung-protective ventilation
Number of subjects: 0
Study: 33304950

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 581
Study: 33305066

Group type: EXPERIMENTAL
Intervention: Laughter prescription (Laughie recording three times daily for 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (only tracking sleep)
Number of subjects: 40
Study: 33305350

Group type: EXPERIMENTAL
Intervention: Weight loss interventions (dietary changes, diet and exercise, diet and psychosocial support, diet, exercise and psychosocial support)
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Weight loss interventions
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Usual care, written materials, placebo, or wait-list controls
Number of subjects: 2028
Study: 33305440

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 89
Study: 33305842

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 to 2000 IU daily; or up to 300,000 IU bolus at enrolment)
Number of subjects: 12122

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 to 6000 IU daily; or up to 600,000 IU bolus at enrolment)
Number of subjects: 12122

Group type: EXPERIMENTAL
Intervention: Higher-dose vitamin D supplementation with micronutrients (400 to 2000 IU daily, or up to 300,000 IU bolus at enrolment)
Number of subjects: 12122

Group type: EXPERIMENTAL
Intervention: Higher-dose vitamin D supplementation
Number of subjects: 12122
Study: 33306031

Group type: EXPERIMENTAL
Intervention: BOOSTH exergame
Number of subjects: 16
Study: 33306036

Group type: EXPERIMENTAL
Intervention: TECH2CHECK intervention (community health nursing visits and SMS messaging)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of Care (SOC) control group
Number of subjects: 120
Study: 33306161

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Without empagliflozin (Control)
Number of subjects: 20
Study: 33306187

Group type: EXPERIMENTAL
Intervention: Tolvaptan (mean daily dose 12.7 mg, mean treatment duration 28.0 days)
Number of subjects: 100
Study: 33306563

Group type: EXPERIMENTAL
Intervention: Community mentor mother visits alone
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Text messages alone
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Preconception ART initiation
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Postconception ART initiation
Number of subjects: 1275
Study: 33306598

Group type: EXPERIMENTAL
Intervention: IL2RA immunohistochemistry (IHC)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: alanine aminotransferase (ALT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IL2RA IHC
Number of subjects: 123
Study: 33306625

Group type: EXPERIMENTAL
Intervention: 99mTc-anti-TNF-α scintigraphy
Number of subjects: 20
Study: 33307033

Group type: EXPERIMENTAL
Intervention: Noninvasive tests (NITs) for fibrosis
Number of subjects: 2154

Group type: EXPERIMENTAL
Intervention: Decrease in NIT scores during treatment
Number of subjects: 2154
Study: 33307107

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), single-dose intravenous infusion
Number of subjects: 30
Study: 33307151

Group type: EXPERIMENTAL
Intervention: 5 fractions of 7.0 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 fractions of 10.0 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1 single fraction of 20.0 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment schedules
Number of subjects: 90
Study: 33307469

Group type: EXPERIMENTAL
Intervention: Elevated CDR (≥11)
Number of subjects: 40
Study: 33307491

Group type: EXPERIMENTAL
Intervention: Logistic regression with elastic net penalty
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: XGBoost tree
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Support Vector Machines (SVM)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 457
Study: 33307957

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33308230

Group type: EXPERIMENTAL
Intervention: Training on person-centered family planning for ASHAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ASHAs (no specific intervention)
Number of subjects: 0
Study: 33308240

Group type: EXPERIMENTAL
Intervention: Chronic severe primary MR patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Asymptomatic chronic severe primary MR patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CMR derived ECV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Autopsy controls
Number of subjects: 120
Study: 33308265

Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 8 Gy in 1 fraction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 10 Gy in 1 fraction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Radiosurgery boost with 10 Gy in 2 fractions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 34
Study: 33308277

Group type: EXPERIMENTAL
Intervention: Shared decision-making process and surrogate decision-making processes in care planning.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed methodology (epidemiological and qualitative research) to explore opposition and refusal of care.
Number of subjects: 0
Study: 33308307

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glutamine
Number of subjects: 30
Study: 33309060

Group type: EXPERIMENTAL
Intervention: Endoscopic VENCH scoring system (V, E, N, C, H scores)
Number of subjects: 4
Study: 33309459

Group type: EXPERIMENTAL
Intervention: Single subanesthetic ketamine infusion
Number of subjects: 33
Study: 33309581

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 794
Study: 33309978

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) alone, doses of 24 to 39.6 Gy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) alone
Number of subjects: 75
Study: 33310179

Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula 2 (FAHF-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive TCM therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple TCM therapy (ingestion, bath, and cream)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xiao Feng San and Japanese and Korean formulas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 33310655

Group type: EXPERIMENTAL
Intervention: Engineered bacteriophages with modified receptor-binding proteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phages as prokaryotic gene therapy vectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Big data and AI-driven approaches for phage design
Number of subjects: 0
Study: 33310795

Group type: EXPERIMENTAL
Intervention: Low first dose of surfactant
Number of subjects: 0

Group type: COMPARATOR
Intervention: High first dose of surfactant
Number of subjects: 0
Study: 33310806

Group type: EXPERIMENTAL
Intervention: HPV-focused Boot Camp Translation (BCT) intervention
Number of subjects: 0
Study: 33310814

Group type: EXPERIMENTAL
Intervention: COVID-19 outbreak period
Number of subjects: 6040

Group type: EXPERIMENTAL
Intervention: Factors associated with stress worsening
Number of subjects: 6040
Study: 33310883

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients with GAD antibodies (9 out of 16 patients proceeded with surgery)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients without GAD antibodies (112 out of 205 patients proceeded with surgery)
Number of subjects: 221
Study: 33311588

Group type: EXPERIMENTAL
Intervention: RO6870810
Number of subjects: 74
Study: 33311959

Group type: EXPERIMENTAL
Intervention: Opioid use during preconception and early pregnancy
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Opioid use detected at different gestational periods
Number of subjects: 1228
Study: 33312142

Group type: EXPERIMENTAL
Intervention: Wagering inducements (€10, €50, €100, or €200)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control condition (no incentive)
Number of subjects: 171
Study: 33312759

Group type: EXPERIMENTAL
Intervention: CART-133 T cell infusion
Number of subjects: 21
Study: 33312766

Group type: EXPERIMENTAL
Intervention: Specific stabilization exercise (SSE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional trunk exercise (TTE)
Number of subjects: 39
Study: 33313307

Group type: EXPERIMENTAL
Intervention: Inhaled epithelial sodium channel inhibitor BI 1265162
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33314078

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1960
Study: 33314716

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) radiomics using k-nearest neighbor (KNN) classifier
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard institutional practice of radical radiotherapy (RT)
Number of subjects: 51
Study: 33314747

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg plus apatinib combined with liposomal paclitaxel 150 mg/m²
Number of subjects: 30
Study: 33314761

Group type: EXPERIMENTAL
Intervention: Ertugliflozin co-administered with mefenamic acid (UGT inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mefenamic acid (MFA)
Number of subjects: 0
Study: 33314777

Group type: EXPERIMENTAL
Intervention: IL-1 blockade with canakinumab
Number of subjects: 1

Group type: COMPARATOR
Intervention: Majeed syndrome
Number of subjects: 1

Group type: COMPARATOR
Intervention: M2-like macrophages from the patient with Majeed syndrome
Number of subjects: 1

Group type: COMPARATOR
Intervention: Accelerated osteoclastogenesis in the patient with Majeed syndrome
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: JNK inhibition and IL-1 blockade
Number of subjects: 1
Study: 33314979

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33315176

Group type: EXPERIMENTAL
Intervention: Machine learning based automated system using EEG features
Number of subjects: 66
Study: 33315277

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) therapy
Number of subjects: 36
Study: 33315296

Group type: EXPERIMENTAL
Intervention: ACURATE neo valve via transaxillary approach
Number of subjects: 75
Study: 33315505

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (Encage™)
Number of subjects: 20
Study: 33315630

Group type: EXPERIMENTAL
Intervention: MAPK pathway inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33315694

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 64
Study: 33315720

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study: 33316105

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 2819
Study: 33316268

Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels (after adjustment for confounders)
Number of subjects: 524
Study: 33316557

Group type: EXPERIMENTAL
Intervention: First-line immunotherapy
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy
Number of subjects: 636

Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 636
Study: 33317503

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of TSIH (TSIHc)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination for TSIH (TSIHu)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for risk factors
Number of subjects: 76
Study: 33317530

Group type: EXPERIMENTAL
Intervention: COPD patients with a rapid decline in lung function
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 12
Study: 33317628

Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring (measured twice a day for 7 days at 4, 8, and 12 weeks)
Number of subjects: 2483

Group type: COMPARATOR
Intervention: Control group (no HBP monitoring)
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring (among those who measured at least once)
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring
Number of subjects: 2483
Study: 33317695

Group type: EXPERIMENTAL
Intervention: Spermidine supplementation in T cells from old donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous spermidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-induced antigen-specific CD8+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSV-induced T cells in older vaccinees
Number of subjects: 0
Study: 33317729

Group type: EXPERIMENTAL
Intervention: Fampridine treatment (responders)
Number of subjects: 49
Study: 33317858

Group type: EXPERIMENTAL
Intervention: Tofacitinib (a Janus kinase 1/3 inhibitor)
Number of subjects: 5
Study: 33318007

Group type: EXPERIMENTAL
Intervention: Aztreonam lysine for inhalation solution (AZLI)
Number of subjects: 0
Study: 33318012

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (15 to 20 mg/kg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (40 mg/kg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (56 mg/kg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (20 to 25 mg/kg/day)
Number of subjects: 105
Study: 33318014

Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 46
Study: 33318032

Group type: EXPERIMENTAL
Intervention: Acute care bundle comprising: (1) ASQ for self-harm risk assessment, (2) HEADS-ED for mental health evaluations, (3) Choice And Partnership Approach for shared decision making.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute care bundle
Number of subjects: 0
Study: 33318123

Group type: EXPERIMENTAL
Intervention: Abnormal EEG patterns during sleep and wakefulness
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: EEG slow wave activity, sleep spindle density, peak frequency of the posterior dominant rhythm
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Postoperative Confusion Assessment Method (CAM) evaluations
Number of subjects: 220
Study: 33318163

Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 23
Study: 33318928

Group type: EXPERIMENTAL
Intervention: Handheld multispectral optoacoustic tomography (MSOT)
Number of subjects: 10
Study: 33319038

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 33319187

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5-10 mg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 33319318

Group type: EXPERIMENTAL
Intervention: HPLC-ninhydrin-photometry (PM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UHPLC-PITC-tandem mass spectrometry (TMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both methods (PM and TMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMS
Number of subjects: 0
Study: 33319384

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in aortopathy genes with implications for family members
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in aortopathy genes that would change medical management
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Actionable secondary findings related to cancer
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Actionable secondary findings related to other cardiac diseases
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Non-actionable findings-pathogenic variants in aortopathy genes that would not change medical management
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance
Number of subjects: 225
Study: 33319471

Group type: EXPERIMENTAL
Intervention: Third/Fourth OBPM (S3S4/D3D4)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Second/Third OBPM (S2S3/D2D3)
Number of subjects: 802
Study: 33319498

Group type: EXPERIMENTAL
Intervention: Durvalumab treatment
Number of subjects: 537
Study: 33319916

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 2319
Study: 33320065

Group type: EXPERIMENTAL
Intervention: Visual presence of mild, moderate, and confluent emphysema at baseline CT in participants with COPD (1655 participants, 40%)
Number of subjects: 4166

Group type: COMPARATOR
Intervention: Baseline CT assessment
Number of subjects: 4166

Group type: COMPARATOR
Intervention: Pulmonary function testing at baseline CT and at 5 years
Number of subjects: 4166

Group type: COMPARATOR
Intervention: Quantitative inspiratory and expiratory CT at baseline and at 5 years
Number of subjects: 4166
Study: 33320102

Group type: EXPERIMENTAL
Intervention: FirstER application-based service
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Current legacy system
Number of subjects: 1000
Study: 33320103

Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention (twice weekly for 8 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention
Number of subjects: 150
Study: 33320245

Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC), median 1.9 mg/day (IQR 0.6-4.2), mean cumulative prednisone dose 8468 mg, mean duration 44.6 months
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC), highest cumulative exposure (≥8.4 g)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids (GC)
Number of subjects: 608

Group type: COMPARATOR
Intervention: No glucocorticoids (GC)
Number of subjects: 608
Study: 33320346

Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (PD)
Number of subjects: 2953
Study: 33320729

Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using the robust Integrated Jacobian Formulation (IJF) method
Number of subjects: 77
Study: 33321118

Group type: EXPERIMENTAL
Intervention: Smartphone app for sBP measurement
Number of subjects: 965

Group type: COMPARATOR
Intervention: Reference device - automated oscillometric cuff device
Number of subjects: 965
Study: 33321200

Group type: EXPERIMENTAL
Intervention: Open conjunctival implantation of the XEN45 Gel Stent
Number of subjects: 137

Group type: COMPARATOR
Intervention: Closed conjunctival implantation of the XEN45 Gel Stent
Number of subjects: 137
Study: 33322606

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement based on 150 mg of resveratrol
Number of subjects: 20
Study: 33323025

Group type: EXPERIMENTAL
Intervention: Interleukin-18 (IL-18) levels measured in serum by enzyme-linked immunosorbent assay.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Liver lipid content assessed by liver-to-spleen computed tomography (CT) attenuation ratio.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST) levels.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT) levels.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (individuals without HIV), 59 participants.
Number of subjects: 125
Study: 33323024

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART)
Number of subjects: 20